



- **21st and 22nd of November 2023**
- **Organizers:** *D Tulasne and A Cortot*
- **Scientific board:** *D. Tulasne, A. Cortot, Z. Kherrouche, F. Maina, S. Kermorgant, A. Maraver*

Tuesday 21st of November

Session 1: MET BIOLOGY IN CANCER

- **9:00 am: Welcome to the “MET in Cancer” Workshop**
MET receptor Signaling in cancer
- **09:30 am: Maina F, Marseille, France.** MET dependent tumor growth in TNBC and HCC
- **10:00 am: Kermorgant S, London, UK.** Dynamic MET signaling
MET exon14 signaling
- **10:30 am: Tulasne D, Lille, France.** MET exon 14 signaling
- **11:00 am: Coffee break**
- **11:30 am: Lockwood WW, Vancouver, Canada.** KRAS signaling in MET ex14
MET and immunity
- **12:00 pm: Giroux Leprieur E, Paris-Saclay University, France.** MET and Immunotherapies
- **12:30 pm: Hieronymus T, RWTH Aachen University, Germany.** MET and immunity
- **1:00-2:30 pm: Buffet and Posters**

Session 2: MET DIAGNOSES

- **2:30 pm: Riccardo Taulli, University of Torino, Italia.** Circulating MET mRNA
- **3:00 pm: Kim So Yeon, New York, USA.** Whole transcriptome sequencing METex14
- **3:30 pm: Coffee break**
- **4:00-6:00 pm: First session of selected talks from abstracts**
- **From 6:00 pm: Poster session**
- **Diner in Lille**

Wednesday 22nd of November

Session 3: MET TARGETING BY TKI AND ANTIBODIES

- **9:00 am: Cortot A, Lille, France,** Efficacy and limits of the MET TKI, International clinical trial
- **9:30 am: Perera T, Liège, Belgium,** New generation MET TKIs
- **10:00 am: Vigna E, Torino, Italia,** MET DN30 antibody
- **10:30 am: Coffee break**
- **11:00 am: Abbvie,** ADC targeting MET
- **11:30 – 1:00 pm: Second session of selected talks from abstracts**
- **1:00-2:00 pm Buffet and Poster**

Session 4: RESISTANCE TO MET TKI

Preclinical models to study resistance

- **2:00 pm : Maraver A, Montpellier, France.** Mice model of EGF TKI resistance involving MET
- **2:30 pm: Toshio F, Charlestown, USA.** Resistance by BAF3 models
- **3:00 pm: Kimple RJ, Madison, USA.** MET exon 14 PDX
- **3h30 pm: Coffee break**

Resistance to MET inhibitors in MET-addicted cancers

- **4:00 pm: Kherrouche Z, Lille, France.** Resistance to MET ex14 TKI through PI3K pathway
- **4:30 pm: Poster Price supported by the Institut Pasteur de Lille and closure remarks**
- **5:00 pm: *Closure***